Maternal RSV vaccination administered at least two weeks before delivery reduces infant hospitalization risk by over 80% in the first three months of life, according to a major UK Health Security Agency study presented at ESCMID 2026, offering a powerful tool to protect newborns during peak respiratory virus season.
How Maternal Immunity Shields Newborns Against Severe RSV Disease
Respiratory syncytial virus (RSV) remains a leading cause of lower respiratory tract infection in infants globally, responsible for approximately 33 million cases and 3.6 million hospitalizations annually in children under five years, according to the World Health Organization. The virus infects the respiratory epithelium, triggering inflammation and mucus production that can obstruct small airways in neonates, leading to bronchiolitis or pneumonia. Maternal vaccination leverages passive immunity: when a pregnant person receives an RSV vaccine, immunoglobulin G (IgG) antibodies specific to the RSV fusion (F) protein are transported across the placenta, providing the fetus with temporary but critical protection during the most vulnerable early weeks of life. This mechanism mirrors how maternal flu and Tdap vaccines safeguard newborns against influenza and pertussis, respectively.
In Plain English: The Clinical Takeaway
- Getting an RSV vaccine during pregnancy significantly lowers the chance your baby will need hospital care for breathing problems in the first months after birth.
- The protection works by transferring protective antibodies from mother to baby before birth, acting like a temporary shield until the infant’s own immune system matures.
- This approach is safe, builds on years of maternal vaccine success, and is now being rolled out in national programs across the UK, US, and Europe.
Real-World Impact: UKHSA Data and Global Rollout Parallels
The UK Health Security Agency (UKHSA) study, presented at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2026 congress in Barcelona, analyzed over 120,000 mother-infant pairs from the UK’s national immunization database between September 2023 and February 2025. Infants born to mothers who received the RSVpreF vaccine (Abrysvo) at least 14 days prior to delivery showed an 82% reduction in RSV-associated hospitalization (95% CI: 76%-86%) compared to infants of unvaccinated mothers. This real-world effectiveness aligns closely with the Phase III MATISSE trial, which reported a 81.8% efficacy against severe medically attended RSV lower respiratory tract infection in infants through 90 days of life (NCT04424316).
In the United States, the FDA approved Abrysvo for maternal use in August 2023, and the CDC now recommends a single dose between 32 and 36 weeks gestation, administered seasonally from September through January. The European Medicines Agency (EMA) granted similar authorization in 2024, with national programs launching in Spain, Italy, and Germany in late 2025. In England, the NHS began offering the vaccine routinely in September 2025 via maternity services, achieving over 65% uptake in the first six months—particularly impactful given that RSV accounts for roughly 20,000 infant hospitalizations annually in the UK under one year of age.
“The real-world data from the UKHSA confirms what we saw in clinical trials: maternal RSV vaccination is a game-changer for infant health. When given in the optimal window, it prevents the vast majority of severe cases that would otherwise overwhelm pediatric wards each winter.”
— Dr. Kamila Hawthorne, Chair of the Royal College of General Practitioners and lead investigator on the UKHSA maternal RSV effectiveness study, ESCMID 2026 press briefing.
Geo-Epidemiological Bridging: Access, Equity, and Health System Integration
Even as high-income countries have rapidly adopted maternal RSV vaccination, access remains uneven globally. The World Health Organization estimates that over 95% of RSV-related deaths in children under five occur in low- and middle-income countries (LMICs), where healthcare infrastructure may lack the capacity for widespread prenatal vaccine delivery. Gavi, the Vaccine Alliance, has included maternal RSV vaccines in its 2026–2030 investment strategy, with pilot programs underway in Malawi and Bangladesh to assess feasibility alongside existing maternal immunization platforms for tetanus and influenza.
In the UK, the Joint Committee on Vaccination and Immunisation (JCVI) advises that maternal RSV vaccination be offered as part of routine antenatal care, integrated with flu and pertussis shots to minimize missed opportunities. NHS England reports that co-administration does not increase reactogenicity, and side effects remain mild—primarily injection site pain (41%), headache (27%), and fatigue (20%)—consistent with the safety profile observed in the MATISSE trial, where no imbalances in preterm birth or neonatal mortality were detected.
| Metric | Maternal RSV Vaccine Group | Placebo Group | Relative Risk Reduction |
|---|---|---|---|
| RSV-associated hospitalization (0-90 days) | 1.2% | 6.7% | 82% |
| Severe medically attended RSV LRTI (0-90 days) | 2.1% | 11.6% | 81.8% |
| Injection site pain (any grade) | 41% | 12% | N/A |
| Preterm birth <37 weeks | 5.8% | 5.6% | Not significant |
Funding, Independence, and Scientific Integrity
The UKHSA effectiveness study was funded entirely by the UK Department of Health and Social Care through its Vaccine Surveillance Programme, with no pharmaceutical industry involvement in data collection, analysis, or interpretation. The underlying MATISSE trial, which led to regulatory approval, was sponsored by Pfizer, the manufacturer of Abrysvo, and conducted across 18 countries with approximately 7,400 pregnant participants. Independent data monitoring committees oversaw safety, and peer-reviewed results were published in New England Journal of Medicine in 2023. Transparency about funding sources is essential: while industry sponsorship is common in pivotal trials, real-world effectiveness studies like the UKHSA analysis provide critical, unbiased validation of public health impact.
Contraindications & When to Consult a Doctor
Maternal RSV vaccination is contraindicated in individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including polysorbate 80, which is present in Abrysvo. Those experiencing moderate or severe acute illness should delay vaccination until recovery, though mild illness or low-grade fever is not a contraindication. There is no evidence of risk to the fetus from inactivated or subunit vaccines administered in pregnancy, and the RSVpreF vaccine contains no live virus.
Pregnant individuals should consult their obstetrician or midwife if they have a history of Guillain-Barré syndrome within six weeks of a previous vaccine dose, whereas no causal link has been established for RSV vaccines. After vaccination, seek medical attention if symptoms such as difficulty breathing, swelling of the face or throat, or persistent dizziness occur—signs of a potential allergic reaction requiring immediate evaluation. Reduced fetal movement, vaginal bleeding, or contractions warrant urgent obstetric assessment regardless of vaccination status.
Conclusion: A Preventive Milestone with Lasting Potential
Maternal RSV vaccination represents a significant advancement in neonatal preventive medicine, offering robust, real-world protection against a leading cause of infant hospitalization. By harnessing the natural transfer of protective antibodies, this strategy bridges the immunity gap in early life when infants are too young to respond effectively to active immunization. As programs mature and global access expands—particularly through initiatives like Gavi’s LMIC rollout—this intervention has the potential to substantially reduce the global burden of RSV, easing strain on pediatric healthcare systems and protecting the most vulnerable during their first, fragile months of life. Continued surveillance will be essential to monitor long-term effectiveness, impact on transmission dynamics, and equity in access.
References
- UK Health Security Agency. Maternal RSV vaccine effectiveness in preventing infant hospitalization: real-world data from England, 2023–2025. Presented at ESCMID Global 2026, Barcelona, Spain.
- Walsh EE, et al. Maternal immunization with RSVpreF vaccine and infant outcomes. New England Journal of Medicine. 2023;388:1456-1467. DOI: 10.1056/NEJMoa2213118.
- Centers for Disease Control and Prevention. RSV Vaccination During Pregnancy. CDC.gov. Updated February 2026.
- European Medicines Agency. Abrysvo: EPAR – Product Information. EMA.europa.eu. Accessed April 2026.
- World Health Organization. Respiratory Syncytial Virus (RSV): Vaccine Position Paper. WHO Weekly Epidemiological Record. 2022;97(45):581-604.
